Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $128,200.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $12.82, for a total value of $128,200.00. Following the completion of the sale, the insider now owns 122,279 shares of the company's stock, valued at approximately $1,567,616.78. This trade represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Centessa Pharmaceuticals Stock Up 0.5%

CNTA stock traded up $0.07 during trading hours on Friday, hitting $13.14. The company's stock had a trading volume of 751,590 shares, compared to its average volume of 660,764. The stock has a 50 day moving average price of $12.73 and a two-hundred day moving average price of $15.32. Centessa Pharmaceuticals plc has a 12 month low of $7.90 and a 12 month high of $19.09. The company has a market capitalization of $1.75 billion, a PE ratio of -8.59 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.15. On average, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in CNTA. Ellsworth Advisors LLC bought a new position in shares of Centessa Pharmaceuticals in the 1st quarter valued at approximately $703,000. Jane Street Group LLC bought a new stake in Centessa Pharmaceuticals during the first quarter worth approximately $2,176,000. Exome Asset Management LLC grew its holdings in Centessa Pharmaceuticals by 3.7% during the first quarter. Exome Asset Management LLC now owns 142,744 shares of the company's stock valued at $2,053,000 after purchasing an additional 5,028 shares during the last quarter. Millennium Management LLC raised its position in shares of Centessa Pharmaceuticals by 52.9% in the first quarter. Millennium Management LLC now owns 609,188 shares of the company's stock valued at $8,760,000 after purchasing an additional 210,737 shares during the period. Finally, Cutter Capital Management LP raised its position in shares of Centessa Pharmaceuticals by 184.3% in the first quarter. Cutter Capital Management LP now owns 418,127 shares of the company's stock valued at $6,013,000 after purchasing an additional 271,051 shares during the period. Institutional investors and hedge funds own 82.01% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CNTA. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a research report on Wednesday. They issued a "buy" rating and a $35.00 price target for the company. Chardan Capital initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued a "buy" rating and a $30.00 price target for the company. Piper Sandler started coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an "overweight" rating and a $38.00 price objective for the company. Oppenheimer began coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 target price on the stock. Finally, Guggenheim reaffirmed a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $27.89.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.